Protalix BioTherapeutics presented data from its Phase 1 clinical trial of PRX-115, a recombinant PEGylated uricase, at the American College of Rheumatology (ACR) Convergence 2024. The study demonstrated prolonged plasma urate-lowering effects after a single intravenous administration in participants with elevated urate levels, suggesting a potential new treatment option for uncontrolled gout.
The late-breaking poster presentation, titled "Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels," was presented by Orit Cohen Barak, Ph.D. from Protalix Ltd.
Key Findings of the Phase 1 Trial
The Phase 1 trial evaluated the safety and efficacy of PRX-115 in lowering serum uric acid levels in patients with uncontrolled gout. The results indicated that a single intravenous dose of PRX-115 led to a sustained reduction in plasma urate levels. The abstract (Abstract Number: L05) is accessible on the ACR Convergence 2024 website.
About PRX-115
PRX-115 is a plant cell-expressed recombinant PEGylated uricase being developed by Protalix BioTherapeutics for the treatment of uncontrolled gout. Gout is a common and painful form of inflammatory arthritis caused by hyperuricemia, where excess uric acid crystallizes and deposits in joints and tissues. Current treatments often fall short in achieving adequate urate lowering for all patients, highlighting the need for novel therapeutic options.
Protalix's Broader Pipeline
Protalix BioTherapeutics utilizes its ProCellEx plant cell-based protein expression system to develop recombinant therapeutic proteins. In addition to PRX-115, their pipeline includes PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases.
